# S4-09 — J1 Pharma Vertical Pack (Standalone)

```
prompt_id: S4-09    stream: 4    sequence: 9 of 16    effort: ~80 min
```

## Pre-flight
S4-00; V9: J1_PHARMACEUTICAL.md (already 600+ lines); cross-refs
H1 §2.1; per H2 + H3 + H8 + H9; D10 (BREL); E15 §2.9 + §2.13;
L1 BD-9..BD-12; L2 (AI-09 anomaly + AI-13 RCA + AI-21 APR
drafting + AI-32 periodic-review brief)

Standards exhaustive:
- 21 CFR Part 11/207/210/211/212/314/600-680/606/803/Part 7
- EU GMP Annex 1/11/13/15/16/17/21
- ICH Q1A-Q14 + E2B(R3)
- WHO TRS 957/992
- DSCSA + EU FMD
- USP <1058> + ISO 14644 (cleanrooms)
- PIC/S Annex 1, 11
- ASTM E2500
- Health Canada Div 2; ANVISA RDC 658
- Regulatory horizon (per H1 §6)

## Deliverable
PART_J_VERTICAL_PACKS/J1_PHARMACEUTICAL.md

## Depth requirements

Sub-vertical taxonomy (≥ 12: API; drug-product solid-oral;
sterile-injectable; inhalation; topical; biologics; cell+gene;
investigational IMP; PET; OTC; compounded; veterinary;
combination; DSCSA participant; EU FMD participant)

Authoritative roots (≥ 30):
APR; Manufacturing Deviation; MBR; EBR; QC Sample; Stability
Study + Pull; ICSR; DSCSA Transaction Set; Serialized Unit;
QP Declaration + Pre-Release Pack; Cleaning Validation Cycle;
EM Run; Media Fill; Water Monitoring; HVAC Qualification;
Aseptic Personnel Qual; PV Case; Recall Decision; FAR; PADER;
REMS; IND Distribution; Master + Working Cell Bank; etc.

State machines (≥ 8):
SM-APR; SM-DEV; SM-STAB; SM-ICSR; SM-DSCSA; SM-CLEANING-V;
SM-EMP (sterile); SM-MEDIA-FILL; SM-RECALL (per BD-8);
SM-FAR; SM-IND-DIST

Per-pack workflows (D1..D14 per pack overlay; substantive)
Per-pack APIs (E15.9 DSCSA + EU FMD; E15.13 ICSR; E15.16
sub-processor)
Per-pack UI (EBR Workspace + AR Shell; APR Workspace; QP
Pre-Release Workspace; Deviation; QC Sample; Stability;
DSCSA Transaction; ICSR; Pharma Audit Pack Wizard;
Cleaning Validation; EM Console (sterile); Media Fill;
Recall Decision Console; FAR; PV Signal Console)

Pack discipline:
- 2-person e-sig BD-1 + BD-9..BD-12
- QP signature per Annex 16
- US Designated Person
- 21 CFR 11.10(j) accountability
- Mandatory reason-for-change
- Validation chain at release
- WORM perpetual + 25-yr GxP
- APR cadence enforcement
- Annex 1 contamination control strategy
- Aseptic re-qualification cycle
- Stability protocol immutability
- DSCSA suspect product 3-day window
- EU FMD verification at dispense
- ICH Q12 lifecycle management

Pack KPIs ≥ 12; Pack failure modes ≥ 8; Audit pack contents
exhaustive (≥ 30 sections per FDA/EMA inspection); RACI per
regulated decision

## Required substance
≥ 12,000 words.

## Acceptance criteria
```
[ ] ≥ 12 sub-verticals; ≥ 30 roots; ≥ 8 SMs
[ ] BD-1, BD-9..BD-12 spec
[ ] DSCSA + EU FMD + ICH E2B(R3) integration
[ ] Annex 1 sterile sub-pack
[ ] Pack discipline ≥ 12 items
[ ] Audit pack ≥ 30 sections
[ ] No marketing
[ ] Decision phrase emitted
```

## Decision phrase
```
S4-09_J1_PHARMA_DEEP_UPGRADE_COMPLETE
```

After: load S4-10_J2_J3.md.
